Organon (OGN) Current Assets (2020 - 2026)
Organon (OGN) posted quarterly Current Assets of $4.9 billion for Q1 2026, up 12.83% year-over-year from $4.4 billion in Q1 2025, and up 13.33% on a QoQ basis from $4.4 billion in Q4 2025.
Organon (OGN) Current Assets (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Current Assets for 7 consecutive years, with $4.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets rose 12.83% year-over-year to $4.9 billion; the TTM figure through Mar 2026 stood at $4.9 billion (up 12.83% YoY), while the FY2025 annual figure was $4.4 billion, changed 0.09% from the prior year.
- Current Assets came in at $4.9 billion for Q1 2026 at Organon, up from $4.4 billion in the prior quarter.
- The five-year high for Current Assets was $4.9 billion in Q1 2026, with the low at $3.6 billion in Q3 2022.
- Average Current Assets over 5 years is $4.2 billion, with a median of $4.3 billion recorded in 2024.
- The largest YoY upside for Current Assets was 24.92% in 2022 against a maximum downside of 17.02% in 2022.
- Year by year, Current Assets stood at $3.9 billion in 2022, then advanced by 14.68% to $4.5 billion in 2023, then retreated by 3.55% to $4.3 billion in 2024, then gained by 0.09% to $4.4 billion in 2025, then grew by 13.33% to $4.9 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $4.9 billion, $4.4 billion, and $4.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 54.84 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 59.17 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 33.53 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 29.61 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 35.02 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 31.48 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 18.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 42.82 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 4.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.93 Bn |
| Dec 31, 2025 | 4.35 Bn |
| Sep 30, 2025 | 4.70 Bn |
| Jun 30, 2025 | 4.62 Bn |
| Mar 31, 2025 | 4.37 Bn |
| Dec 31, 2024 | 4.35 Bn |
| Sep 30, 2024 | 4.76 Bn |
| Jun 30, 2024 | 4.51 Bn |
| Mar 31, 2024 | 4.20 Bn |
| Dec 31, 2023 | 4.51 Bn |
| Sep 30, 2023 | 4.05 Bn |
| Jun 30, 2023 | 3.96 Bn |
| Mar 31, 2023 | 3.78 Bn |
| Dec 31, 2022 | 3.93 Bn |
| Sep 30, 2022 | 3.59 Bn |
| Jun 30, 2022 | 3.77 Bn |
| Mar 31, 2022 | 3.72 Bn |
| Dec 31, 2021 | 3.76 Bn |
| Sep 30, 2021 | 4.33 Bn |
| Jun 30, 2021 | 3.91 Bn |